Pricing Log in Create free account

CG Oncology, Inc. (CGON) vs Erasca, Inc. (ERAS)

CG Oncology, Inc. and Erasca, Inc. are both Biotechnology companies. CG Oncology, Inc. is the larger, with a market value of $5.7B against $4.6B — 1.2× the size. Erasca, Inc. has the higher net margin (0.00% vs −3,851.1%) and the higher return on invested capital (−203.1% vs −1,740.2%). Across the 13 metrics below, Erasca, Inc. leads on 7 and CG Oncology, Inc. on 6.

Valuation

Metric CGON ERAS Biotechnology median
P/E n/m n/m 10.60
P/S 1,096.55 n/m 9.40
P/B 6.82 12.34 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 938.83 n/m 9.02
Earnings yield (3.63%) (6.62%) (32.88%)
Free cash flow yield (2.80%) (5.65%) (23.13%)

Profitability

Metric CGON ERAS Biotechnology median
Gross margin 0.00% 0.00% 68.51%
Operating margin (4,293.53%) 0.00% 0.00%
Net margin (3,851.09%) 0.00% 0.00%
Free cash flow margin (3,068.02%) 0.00% 0.00%
Return on equity (28.29%) (78.25%) (51.96%)
Return on assets (26.73%) (65.25%) (46.06%)
Return on invested capital (1,740.24%) (203.13%) 0.00%

Growth

Metric CGON ERAS Biotechnology median
Revenue growth (TTM) 178.12% — 6.76%
EPS growth (last fiscal year) (47.52%) 36.23% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CGON ERAS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 21.70 8.29 4.97
Net debt to EBITDA 3.88 1.93 1.01

Dividend

Metric CGON ERAS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CGON ERAS Biotechnology median
Market cap 5.74b 4.64b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack